Holen Sie sich die Stockscreener-App
33.09
1.61%
-0.54
Schlusskurs vom Vortag:
$33.63
Offen:
$33.62
24-Stunden-Volumen:
577.55K
Relative Volume:
0.51
Marktkapitalisierung:
$1.98B
Einnahmen:
$66.05M
Nettoeinkommen (Verlust:
$-422.60M
KGV:
-4.5635
EPS:
-7.251
Netto-Cashflow:
$-384.73M
1W Leistung:
-1.40%
1M Leistung:
-11.43%
6M Leistung:
+13.13%
1J Leistung:
-13.38%
1-Tages-Spanne:
$32.95
$34.09
1-Wochen-Bereich:
$32.95
$35.98
52-Wochen-Spanne:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
33.09 | 2.01B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Bestätigt | H.C. Wainwright | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Bank of America Corp DE Sells 31,441 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO) - Seeking Alpha
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate - Moomoo
Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes - Sahm
612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC - MarketBeat
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Agios Pharmaceuticals (AGIO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Responsive Playbooks and the AGIO Inflection - Stock Traders Daily
FARALLON CAPITAL MANAGEMENT LLC Adds to Agios Pharmaceuticals In - GuruFocus
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds - Sahm
AGIO Maintained by JP Morgan -- Price Target Raised to $34 - GuruFocus
Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co. - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Agios Pharmaceuticals, Inc. (AGIO) And Encourages Investors to Connect - ACCESS Newswire
Agios Pharmaceuticals (AGIO) Chief Medical Officer Sarah Gheuens Sells 30,000 Shares - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 30,000 Shares - MarketBeat
Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade - Stock Titan
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - simplywall.st
AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares - stocktitan.net
Dimensional Fund Advisors LP Increases Position in Agios Pharmaceuticals, Inc. $AGIO - marketbeat.com
Agios Pharmaceuticals (AGIO) Stock Analysis: High Potential Upside In The Biotech Sector - DirectorsTalk Interviews
Farallon Capital (AGIO) discloses 5.9M-share, 9.9% position in Agios - Stock Titan
Seven Fleet Capital Management LP Has $7.09 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Price to sales forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO - TradingView
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $39 - Moomoo
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $39 to $55 - Moomoo
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year - Yahoo Finance
AGIO: Q2 2026 delivered $44.7M revenue, strong AQVESME launch, and pipeline progress with ~$1B cash - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - PR Newswire
Agios Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Agios Pharmaceuticals reports $44.7M Q2 product revenue, $100.7M net loss, $964.8M cash - TradingView
Agios Pharmaceuticals: Q2 Earnings Snapshot - Barchart.com
Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO) - Yahoo Finance
AGIO|Agios Pharmaceuticals Inc|Price:36.308|Chg%:-0.662 - TradingKey
Agios Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Understanding the Setup: (AGIO) and Scalable Risk - Stock Traders Daily
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo Finance
200,000 Shares in Agios Pharmaceuticals, Inc. $AGIO Bought by Eversept Partners LP - MarketBeat
Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agios Pharmaceuticals Inc (AGIO) Cash Flow - TradingKey
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
1.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):